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CONCLUSIONS:Our data demonstrated that acute and chronic AMR showed clear
signs of accelerated tubular ageing (Inflammaging), with increased number of tubular
p16INK4aþ senescent cells. Moreover, soluble serum factors from graft recipients such
as Complement C5amight be responsible for inducing premature tubular aging.
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INTRODUCTIONANDAIMS: Several studies have reported that renal transplant
patients treated with mTOR inhibitors may experience pulmonary fibrosis-associated
adverse effects (including BOOP). Although epithelial to mesenchymal transition
(EMT) of airway cells has a central role in this process, the complete biological machi-
nery involved is not completely clarified.
METHODS: In order to improve our knowledge on this process, primary wild-type
bronchial epithelial cells (BE63/3) were treated with 5 and 100 nM of EVE for 24 hours.
The expression of major EMTmarkers (a-SMA, Vimentin, Fibronectin) were meas-
ured by RT-PCR and western blot. Transepithelial resistance was measured by a
Millicell-ERS ohmmeter. mRNA andmicroRNA profiling were performed by Illumina
and Agilent kit, respectively.
RESULTS:High dosage EVE caused EMT and reduced the transepithelial resistance.
Gene expression profiling showed that after treatment with EVE 100 nM, 125 genes
were differentially expressed. Enrichment analysis revealed that these genes belong to
44 pathways (including collagen synthesis andmetabolism). Connective tissue growth
factor (CTGF) was a high selected gene. Treatment with 5 nM EVE did not cause any
effect on pro-fibrotic pathways. Three miRNAs resulted up-regulated after EVE 100
nM treatment and able to regulate 31 of the genes selected by the transcriptomic analy-
sis (including CTGF). RT-PCR and western blot for MMP12 and CTGF validated
microarrays.
CONCLUSIONS: These results confirmed our previous published data reporting the
pro-fibrotic activity of high dosage EVE in patients and showed an EVE-related multi-
factorial biological machinery associated with the above-mentioned process. CTGF
seemed to have a central role in this process and a possible new therapeutic candidate.
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INTRODUCTIONANDAIMS: After transplantation, cell-free DNA derived from the
donor organ (ddcfDNA) can be detected in the recipient’s circulation.We aimed to
investigate plasma ddcfDNA levels in renal transplant recipients with a stable graft
function after transplantation and transplant recipients with an acute rejection (AR)
episode.
METHODS: Plasma samples were collected longitudinally from day 1 until 3 months
after transplantation from 107 renal transplant recipients within a multicenter set-up.
Renal surveillance and indication biopsies were histologically evaluated by a single
pathologist according to the Banff classification. Cell-free DNA from the donor was
quantified in plasma by next generation sequencing as a fraction of total cell-free DNA
using a targeted, multiplex PCR basedmethod for the analysis of donor-specific SNPs.
For the current analysis, recipients with an AR episode and stable renal transplant
recipients without acute kidney injury on all study follow-up visits and without fluctua-
tions in plasma ddcfDNA fractions were selected.
RESULTS: Forty-two (39.3%) subjects were categorized as stable renal transplant
recipients. Within this group, median baseline plasma ddcfDNA levels of 0.49%
(0.14%-0.96%) were reached approximately three weeks after transplantation.
Fourteen (13.1%) recipients developed one or two AR episodes. Plasma ddcfDNA
kinetics from 13 recipients with samples available before rejection treatment are shown
in Figure 1. Four recipients developed an episode of a treated borderline rejection (Fig.
1A) on surveillance or indication biopsy with median ddcfDNA fractions of 0.42%
(0.31%-0.56%) at time of rejection. Six Banff IIA rejection episodes were identified in
five recipients. Levels of ddcfDNA were increased during two Banff IIA episodes (Fig.
1B). In one recipient, plasma ddcfDNA increased up to 1.19%while levels increased to
5.17% in another recipient with a Banff IIA rejection episode already four days after
transplantation. Six episodes of antibody-mediated rejection (ABMR) or mixed cellular
AR and ABMRwere identified in four recipients (Fig. 1C). Increased ddcfDNA frac-
tions were observed during four out of these six episodes with median ddcfDNA frac-
tions of 20.29% (1.43%-53.64%).
CONCLUSIONS:Within 3 weeks after transplantation, plasma ddcfDNA fractions
decrease to a stable baseline level. In recipients with an AR, increased levels of ddcfDNA
seem phenotype dependent as higher levels are observed during an acute ABMR or a
mixed cellular AR and ABMR episode compared to Borderline or Banff IIA rejection
episodes.
FP696 ISOLATED V-LESION EARLY AFTER KIDNEY
TRANSPLANTATION MAY NOT TRULY REPRESENT A
REJECTION
Mariana Wohlfahrtova5, Petra Hruba6, Marek Novotny5, Jiri Klema2,
Zdenek Krejcik7, Viktor Stranecky1, Eva Honsova3, Petra Vichova4,
Ondrej Viklicky5
1Inst. of Inherited Metabolic Disorders, 1st Faculty of Medicine Charles University and
General Faculty Hospital, Prague, Czech Republic, 2Dept. of Computer Science, Czech
Technical University, Prague, Czech Republic, 3Dept. of Clinical and Transplant
Pathology, IKEM, Prague, Czech Republic, 4Dept. of Immunogenetics, IKEM, Prague,
Czech Republic, 5Dept. of Nephrology, IKEM, Prague, Czech Republic, 6Transplant
Laboratory, IKEM, Prague, Czech Republic and 7UHKT, Institute of Haematology and
Blood Transfusion, Prague, Czech Republic
INTRODUCTIONANDAIMS:Acute vascular rejection (AVR) is known to be a nega-
tive prognostic factor for kidney allograft survival. However, a role of early isolated v-
lesion (IV) defined as intimal arteritis with minimal tubulointerstitial inflammation
(TI) is unclear. While some authors believe in hidden ischemic/reperfusion injury,
others are convinced of its rejection origin. To help resolve if IV truly represents acute
rejection, molecular profiling of IV and T-cell mediated vascular rejection (TCMRV)
was performed.
METHODS:Gene expression profile of early IV (n¼6) and TCMRV (n¼4) within 1st
month after kidney transplantation was compared usingmicroarrays (Illumina
HumanHT-12 v4 Expression BeadChips).
RESULTS:Usingmicroarray-based gene expression profiling in a training set of
patients, we identified 288 upregulated and 22 downregulated genes in early TCMRV
compared to IV (Fig.1). These dysregulated genes were primarily associated with T and
B cell activation, costimulation, differentiation, receptor signalling pathway, antigen
processing and presentation indicating higher innate and adaptive immune response
and inflammation in early TCMRV biopsies. Hierarchical clustering (Fig 2) and princi-
pal component analysis applied to the whole microarray data indicated a clear distinc-
tion in kidney allografts with TCMRV and IV. Our findings were verified in an
independent validation set of patients (n¼20) using RT-qPCR and confirmed
increased expression of genes associated with immunity and inflammation in TCMRV.
CONCLUSIONS: Early IV has transcriptional profile of immune injury of significantly
lower extend compared toTCMRV. According to this genome-wide transcriptome
analysis early IVmay feature non-rejection phenotype. Our findings provide a resource
for better understanding the origin of IV and are in agreement with recent literature
evidence which shows that intimal arteritis has probably less importance in diagnostics
of TCMR than TI infiltrate. The study results call for reassessment of current histopa-
thology classification which considers intimal arteritis to be at least grade 2 of TCMR
irrespective of TI inflammation. Supported byMinistry of Health of the Czech
Republic, grant nr. 15-26519A and 17-29992A.
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